| Chronic Kidney Diseases
Farxiga vs Renvela
Side-by-side clinical, coverage, and cost comparison for chronic kidney diseases.Deep comparison between: Farxiga vs Renvela with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRenvela has a higher rate of injection site reactions vs Farxiga based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Renvela but not Farxiga, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Farxiga
Renvela
At A Glance
Oral
Once daily
SGLT2 inhibitor
Oral
Three times daily with meals
Phosphate binder
Indications
- Chronic Kidney Diseases
- Heart failure
- Diabetes Mellitus, Non-Insulin-Dependent
- Chronic Kidney Diseases
Dosing
Chronic Kidney Diseases, Heart failure 10 mg orally once daily.
Diabetes Mellitus, Non-Insulin-Dependent Starting dose 5 mg orally once daily; may be increased to 10 mg orally once daily for additional glycemic control. Not recommended when eGFR is less than 45 mL/min/1.73 m2 for glycemic control.
Chronic Kidney Diseases (Adults) Starting dose 0.8-1.6 g orally three times daily with meals based on serum phosphorus level; titrate by 0.8 g per meal at two-week intervals to achieve target serum phosphorus.
Chronic Kidney Diseases (Pediatric, >=6 years) Starting dose 0.8-1.6 g three times daily with meals based on body surface area (BSA) category; titrate based on BSA category at two-week intervals for 6 weeks then every 4 weeks as needed.
Contraindications
- Previous serious hypersensitivity reaction to dapagliflozin or any excipient in FARXIGA
- Bowel obstruction
- Known hypersensitivity to sevelamer carbonate, sevelamer hydrochloride, or any excipient
Adverse Reactions
Most common (>=2%) Female genital mycotic infections, nasopharyngitis, urinary tract infections, back pain, increased urination, male genital mycotic infections, nausea, influenza, dyslipidemia, constipation, discomfort with urination, pain in extremity
Serious Diabetic ketoacidosis, volume depletion, urosepsis and pyelonephritis, hypoglycemia with concomitant insulin or insulin secretagogues, necrotizing fasciitis of the perineum (Fournier's Gangrene), hypersensitivity reactions including anaphylaxis and angioedema
Postmarketing Necrotizing fasciitis of the perineum (Fournier's Gangrene), urosepsis and pyelonephritis, ketoacidosis, acute kidney injury, rash
Most common (>5%) Vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, constipation
Postmarketing Hypersensitivity, pruritus, rash, abdominal pain, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, fecal impaction, ileus, intestinal obstruction, intestinal perforation
Pharmacology
SGLT2 inhibitor; dapagliflozin inhibits sodium-glucose cotransporter 2 in the proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion, while also reducing sodium reabsorption to lower cardiac pre- and afterload, suppress sympathetic activity, and decrease intraglomerular pressure via tubuloglomerular feedback.
Sevelamer carbonate is a non-absorbed phosphate-binding cross-linked polymer, free of metal and calcium, that binds phosphate in the gastrointestinal tract via ionic and hydrogen bonding, thereby decreasing phosphate absorption and lowering serum phosphorus concentrations.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Farxiga
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (11/12)
Renvela
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (4/12) · Qty limit (9/12)
UnitedHealthcare
Farxiga
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Renvela
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Farxiga
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Renvela
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Heart Failure - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Renvela.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FarxigaView full Farxiga profile
RenvelaView full Renvela profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.